The latest market price and purchasing channel recommendations of furmonertinib

Furmonertinib (furmonertinib) is a third-generation EGFR-TKI targeted drug independently developed in China. It is mainly used for patients with EGFR mutation-positive non-small cell lung cancer. It can effectively inhibit T790M drug-resistant mutations in clinical practice, delay disease progression, and provide patients with new treatment options. The launch of fumetinib has enriched the types of targeted therapeutic drugs for lung cancer in China and improved patient accessibility and treatment convenience.

In the domestic market, fumetinib has been included in medical insurance, which means that eligible patients can reduce their personal medical expenses through medical insurance reimbursement. The price of medicines is about more than 2,000 yuan per box. The specific price may vary depending on the hospital, region and purchasing channel. After being included in medical insurance, patients can purchase fumetinib in regular hospital pharmacies, thus ensuring that the source of the drug is regular, safe and reliable.

In terms of purchasing channels, patients should give priority to large domestic public hospitals and certified chain pharmacies to ensure drug quality and medication safety. In addition, you can enjoy medical insurance reimbursement policies when purchasing drugs through hospital prescriptions, while avoiding the risks of counterfeit or inferior drugs that may arise from purchasing through informal channels. For situations where hospital stocks in some areas are limited, you can also consult and purchase through inter-provincial dispensing at regular medical institutions or online pharmacies.

Overall, fumetinib is reasonably priced in the domestic market and is included in medical insurance, and its purchase channels are formal and safe. Patients should strictly follow the doctor's prescription during use and regularly review tumor markers and imaging indicators to ensure the effectiveness and safety of the medication. At the same time, reasonable planning of treatment cycles and dose adjustments can maximize the efficacy of fumetinib in the treatment of lung cancer.

Reference materials:https://www.drugs.com/